Rafael López Castro
Grupo Español de Cáncer de Pulmón · 195 works · 2,223 citations · h-index 21
Top works
- Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer
- A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
- Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)
- Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study)
- Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)
- Lung cancer symptoms at diagnosis: results of a nationwide registry study
- Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry
- A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
- Lung cancer patients with COVID-19 in Spain: GRAVID study
- Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations
- MA03.08 Impact of COVID-19 Pandemic in the Diagnosis and Prognosis of Lung Cancer
- Incidence, predictors and prognostic significance of thromboembolic disease in patients with advancedALK-rearranged non-small cell lung cancer
- KRAS Mutation Status in Non-Small Cell Lung Cancer Distribution Across Occupational Categories
- Tonic–Clonic Seizure as the Presentation Symptom of Severe Hypocalcemia Secondary to Zoledronic Acid Administration
- SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020)
- MA10.01 Antibiotic Use and PD-1 Inhibitors: Shorter Survival in Lung Cancer, Especially When Given Intravenously. Type of Infection Also Matters
- Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation
- Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer
- SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2021)
- Phase II multicenter, single arm, open label study of nivolumab in combination with ipilimumab in untreated patients with metastatic uveal melanoma (GEM1402.NCT02626962)